A pilot study of CHOP plus alemtuzumab for the primary treatment of ALK-ve peripheral T cell lymphoma.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHOP-Campath
- 07 Jun 2017 Biomarkers information updated
- 17 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by UKCRN.
- 04 May 2012 Planned end date changed from 30 Apr 2012 to 2 May 2012 as reported by UKCRN.